Gossamer Bio Is Maintained at Buy by Goldman Sachs
Gossamer Bio Analyst Ratings
H.C. Wainwright Maintains Gossamer Bio(GOSS.US) With Buy Rating, Maintains Target Price $10
Gossamer Bio Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Buy Rating for Gossamer Bio: Seralutinib's Transformative Potential in Pulmonary Hypertension
Gossamer Bio Analyst Ratings
Piper Sandler Sticks to Their Buy Rating for Gossamer Bio (GOSS)
Gossamer Bio Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Gossamer Bio, Maintains $10 Price Target
Gossamer Bio's Strategic Focus on PAH Unmet Needs and Seralutinib Efficacy Drives Buy Rating
Gossamer Bio (GOSS) Gets a Buy From Oppenheimer
HC Wainwright & Co. Reiterates Buy on Gossamer Bio, Maintains $10 Price Target
Gossamer Bio Analyst Ratings
Promising Progress and Expansion Potential of Gossamer Bio's Seralutinib Drive Buy Rating
Oppenheimer Maintains Gossamer Bio(GOSS.US) With Buy Rating, Raises Target Price to $9
Gossamer Bio Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Goldman Sachs Maintains Gossamer Bio(GOSS.US) With Buy Rating, Maintains Target Price $8
Buy Rating Affirmed for Gossamer Bio Amidst Financial Growth and Clinical Advancements
Barclays Reaffirms Their Hold Rating on Gossamer Bio (GOSS)
Gossamer Bio Analyst Ratings